DU8 Stock Overview
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.06 |
| 52 Week High | AU$0.30 |
| 52 Week Low | AU$0.048 |
| Beta | 0.37 |
| 1 Month Change | -12.41% |
| 3 Month Change | 17.65% |
| 1 Year Change | 20.00% |
| 3 Year Change | -92.00% |
| 5 Year Change | -70.00% |
| Change since IPO | -99.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| DU8 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -37.2% | -0.9% | 0.5% |
| 1Y | 20.0% | -11.6% | 1.3% |
Return vs Industry: DU8 exceeded the German Life Sciences industry which returned -9% over the past year.
Return vs Market: DU8 exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| DU8 volatility | |
|---|---|
| DU8 Average Weekly Movement | 30.6% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DU8's share price has been volatile over the past 3 months.
Volatility Over Time: DU8's weekly volatility has decreased from 82% to 31% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 60 | Simon Morriss | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| DU8 fundamental statistics | |
|---|---|
| Market cap | €9.24m |
| Earnings (TTM) | -€7.72m |
| Revenue (TTM) | €6.22m |
1.5x
P/S Ratio-1.2x
P/E RatioIs DU8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DU8 income statement (TTM) | |
|---|---|
| Revenue | AU$10.24m |
| Cost of Revenue | AU$3.94m |
| Gross Profit | AU$6.30m |
| Other Expenses | AU$19.01m |
| Earnings | -AU$12.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 61.50% |
| Net Profit Margin | -124.08% |
| Debt/Equity Ratio | 0% |
How did DU8 perform over the long term?
See historical performance and comparison